AVM Biotechnology – a clinical stage company founded in 2008 – is advancing
AVM0703 in an adaptive design expansion cohort clinical trial in
patients with Non-Hodgkin’s Lymphoma/Leukemia. Led by a
strong executive leadership team and global scientific advisory
board, the company is planning for a direct commercial launch
as well as developing its lead drug, AVM0703, as an ‘off-the-shelf’ cell
therapy product with broad applications in cancer, autoimmune
diseases, and other indications.